MarketPulse

EMA approval

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Johnson & Johnson

J&J Seeks EMA Approval for TECVAYLI as First-Line Monotherapy in Multiple Myeloma

Johnson & Johnson submits EMA application for TECVAYLI monotherapy in relapsed/refractory multiple myeloma, citing 71% risk reduction in disease progression or death versus standard care.
JNJEMA approvalPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··X4 Pharmaceuticals, Inc.

EMA Committee Backs Mavorixafor for WHIM Syndrome, First European Therapy

EMA committee endorses mavorixafor (XOLREMDI) for WHIM syndrome treatment, marking first approved therapy in Europe. Final Commission approval expected Q2 2026.
XFORWHIM syndromemavorixafor